On January 30, GLONGHUI | Canaan Technology (300412.SZ) announced that it expects a net loss of 19 million yuan to 28 million yuan in 2023, deducting non-net loss of 30 million yuan to 39 million yuan, and operating income of 100 million yuan to 115 million yuan.
R&D investment in high-end intelligent pharmaceutical equipment technology and products is high, leading to an increase in R&D costs and labor costs, which affects current performance. Due to the impact of the market environment, the gross margin of sales of some products decreased. At the same time, depreciation and amortization of new fixed assets and intangible assets increased the cost of products, which had a certain impact on the company's net profit.